Baikal skullcap Scutellaria baicalensis Georgi
Also called: Chinese skullcap, huang qin
Baikal (Chinese) skullcap is a perennial herb whose root, huang qin, is used in traditional Chinese medicine, often in combination formulas. It is a different species from American skullcap (Scutellaria lateriflora), whose leaves and stems are used.
- Category
- Botanical
- Part used
- Root
- Strongest evidence
- C Limited
- Native range
- Native from Siberia to the Russian Far East and Vietnam (POWO: "Siberia to Russian Far East and Vietnam")
- Reviewed
- 2026-10-29
Class 3 Limited studies in people. This entry cites 1 RCT of Baikal skullcap root alone (source [4]: a placebo-controlled crossover trial of 3.52 g/day added to metformin). The baicalin trial (source [5]) tested one purified compound, and the other human data it cites come from multi-ingredient products. [4]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHeart and blood vessels1 topic
CBlood sugar and weight1 topic
CBones and joints1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Glucose tolerance in type 2 diabetes (added to metformin) | C | A randomized placebo-controlled crossover trial (3.52 g/day, 8-week periods) in patients already on metformin reported better glucose tolerance with the root; some participants had raised liver enzymes. [4] |
| Blood lipids in coronary artery disease with rheumatoid arthritis (purified baicalin) | C | A 12-week placebo-controlled trial in 374 patients found 500 mg/day purified baicalin lowered triglycerides, total cholesterol and hs-CRP; this tested one compound, not the whole herb. [5] |
| Osteoarthritis symptoms (multi-ingredient supplement) | C | MSK reports that an herbal supplement containing S. baicalensis reduced osteoarthritis symptoms, but it is not known whether the herb alone would have similar effects. [1] |
Main constituents: Flavonoids baicalin (the main flavonoid), baicalein and wogonin [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 3.52 g/day of the root for 8 weeks, added to metformin, in a crossover trial in type 2 diabetes. [4]
- 500 mg/day of purified baicalin for 12 weeks. [5]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)See details
LiverTox has no separate chapter for this species; its Skullcap chapter (American skullcap, likelihood category B …
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines3 listed
Statins; Anticoagulants and antiplatelet drugs; CYP1A2 and CYP2C19 substrates
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications1 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- MSK lists hepatotoxicity and pneumonitis as adverse reactions, with case reports of acute liver injury in patients with arthritis who took a formula containing baicalin. [1]
- Two case reports of liver injury that resolved after stopping a joint supplement containing Chinese skullcap and black catechu; the authors judged Chinese skullcap the most likely cause (Naranjo score 6, probable). [3]
- LiverTox's Skullcap chapter covers American skullcap; it notes that Chinese skullcap is a different species but may also have adverse effects on the liver. [2]
- Single doses of 100-2800 mg of the isolated flavonoid baicalein were well tolerated by 72 healthy adults, with only mild adverse events. [6]
Interactions
| With | What happens |
|---|---|
| Statins | In healthy volunteers, baicalin decreased blood levels of statin drugs. [1] |
| Anticoagulants and antiplatelet drugs | Lab studies suggest baicalin has antithrombotic activity and may add to these drugs; clinical relevance not determined. [1] |
| CYP1A2 and CYP2C19 substrates | Wogonin inhibits these enzymes in vitro; clinical relevance not determined. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements before they are marketed; firms are responsible for the safety and labeling of their products. [9]
- Canada: Scutellaria baicalensis root (huang qin, Radix Scutellariae) is listed in Health Canada's Traditional Chinese Medicine Ingredients monograph (May 29, 2026). [8]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Baicalin, baicalein, wogonin Flavonoids [P4]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 1 entry naming Scutellaria baicalensis: NDI 779, submitted 2012-11-06, a combination with other herbal extracts. Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P1]
- Three further entries (NDI 150, 187 and 296, submitted 2002-2004) name "root of skullcap" without stating a species. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC classification of Baikal skullcap (Scutellaria baicalensis) was found in the IARC Monographs list of classifications (Volumes 1–142, list updated 2026-07-23; checked 2026-10-29). [P2]
- No NTP technical report (2-year study) on Baikal skullcap (Scutellaria baicalensis) was found in NTP's list of technical reports (checked 2026-10-29). [P8]
Liver (NIH LiverTox)
- LiverTox has no separate chapter for this species; its Skullcap chapter (American skullcap, likelihood category B; updated March 28, 2020) notes that Chinese skullcap is a different species but may also have adverse effects on the liver. [P3]
- Two published case reports (2010) of liver injury, judged probable, with a joint supplement containing Chinese skullcap; both resolved after stopping. [P5]
Interactions with medicines
- Statins: Baicalin decreased statin blood levels in healthy volunteers. [P4]
- Anticoagulants and antiplatelet drugs: Baicalin antithrombotic in lab studies; clinical relevance not determined. [P4]
- CYP1A2 and CYP2C19 substrates: Wogonin inhibits these enzymes in vitro; clinical relevance not determined. [P4]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of each component that is a dietary ingredient — Required by 21 CFR 111.75(a)(1)(i) unless FDA grants an exemption petition under 111.75(a)(1)(ii) [P7]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- After single oral doses of baicalein (100-2800 mg) in healthy adults, median Tmax was 0.75-3.5 h and half-life 1.90-15.01 h; urinary clearance was under 1%, and about 27% was eliminated unchanged in feces. [P6]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- LiverTox (NIDDK). Skullcap (last update March 28, 2020), 2020-03-28. ncbi.nlm.nih.gov
- Memorial Sloan Kettering Cancer Center. About Herbs: Scutellaria baicalensis (last updated February 10, 2022), 2022-02-10. mskcc.org
- Linnebur SA, et al. Hepatotoxicity associated with Chinese skullcap contained in Move Free Advanced dietary supplement: two case reports and review of the literature. Pharmacotherapy 2010;30(7):750, 258e-262e (PMID 20586134), 2010-07. pubmed.ncbi.nlm.nih.gov
- Li M, et al. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. J Ethnopharmacol 2014;156:210-5 (PMID 25219601), 2014-10-28. pubmed.ncbi.nlm.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
- National Toxicology Program. Technical Reports (list of TR studies; checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
Sources
- Memorial Sloan Kettering Cancer Center. About Herbs: Scutellaria baicalensis (last updated February 10, 2022), 2022-02-10. mskcc.org
- LiverTox (NIDDK). Skullcap (last update March 28, 2020), 2020-03-28. ncbi.nlm.nih.gov
- Linnebur SA, et al. Hepatotoxicity associated with Chinese skullcap contained in Move Free Advanced dietary supplement: two case reports and review of the literature. Pharmacotherapy 2010;30(7):750, 258e-262e (PMID 20586134), 2010-07. pubmed.ncbi.nlm.nih.gov
- Shin NR, et al. Combined effects of Scutellaria baicalensis with metformin on glucose tolerance of patients with type 2 diabetes via gut microbiota modulation. Am J Physiol Endocrinol Metab 2020;318(1):E52-E61 (PMID 31770016), 2020-01-01. pubmed.ncbi.nlm.nih.gov
- Hang Y, et al. Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Lipids Health Dis 2018;17(1):146 (PMID 29935544), 2018-06-23. pubmed.ncbi.nlm.nih.gov
- Li M, et al. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects. J Ethnopharmacol 2014;156:210-5 (PMID 25219601), 2014-10-28. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Scutellaria baicalensis Georgi (accessed 2026-10-29; native range: "Siberia to Russian Far East and Vietnam"), 2026-10-29. powo.science.kew.org
- Health Canada, NNHPD. Traditional Chinese Medicine Ingredients monograph (date May 29, 2026), 2026-05-29. webprod.hc-sc.gc.ca
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.